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Available online 30 March 2018Transcription factor 7-like 2 (TCF7L2) is the main susceptibility gene for type 2 diabetes, primarily through
impairing the insulin secretion by pancreatic β cells. However, the exact in vivomechanisms remain poorly un-
derstood. We performed a family study and determined if the T risk allele of the rs7903146 in the TCF7L2 gene
increases the risk of type 2 diabetes based on real-time stable isotope measurements of insulin synthesis during
an Oral Glucose Tolerance Test. In addition, we performed oral minimal model (OMM) analyses to assess insulin
sensitivity and β cell function indices. Compared to unaffected relatives, individuals with type 2 diabetes had
lower OMM indices and a higher level of insulin synthesis. We found a T allele-dosage effect on insulin synthesis
and on glucose tolerance status, therefore insulin synthesiswas higher among T-allele carrierswith type 2 diabe-
tes than inwild-type individuals. These results suggest that hyperinsulinemia is not only an adaptation to insulin
resistance, but also a direct cause of type 2 diabetes.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Genetics of type 2 diabetes1. Introduction
Type 2 diabetes has becomeone of themain threats to humanhealth
in the 21st century (Zimmet et al., 2001). This complex disease results
from interactions between lifestyle and genes that are predominantly
involved in the development or function of the insulin-secreting pan-
creatic β cells (Nolan et al., 2011, Ashcroft and Rorsman, 2012). The
rs7903146 T allele of transcription factor 7-like 2 (TCF7L2), a Wnt-
signaling transcription factor gene, has consistently been linked to
type 2 diabetes across different ethnicities (Grant et al., 2006,
Helgason et al., 2007, Lin et al., 2016).
The results of several studies that have looked at the effects of the
TCF7L2 variant suggest that it has a context-dependent inﬂuence on
the availability of insulin. For example, obesity, insulin resistance, and
hyperglycemia appear to enhance the effects of the TCF7L2 variant
(Florez et al., 2006, Wang et al., 2007, Alibegovic et al., 2010, Giannini
et al., 2014, Heni et al., 2010). While the reasons underlying the
context-dependent inﬂuence of the TCF7L2 variant are largely un-
known, several mechanisms have been proposed for how they mightglomerular ﬁltration rate; FSR,
ss spectrometry; IAC, immuno-
; OMM, oral minimal model; SI,
racer/tracee ratio; TCF7L2, tran-
icine, ErasmusMC, RoomD435,
rands).
. This is an open access article undercontribute to type 2 diabetes. TCF7L2 variants have been associated
with impaired incretin-stimulated insulin secretion (Faerch et al.,
2013, Schafer et al., 2007, Shu et al., 2009) and with increased hepatic
glucose production (Boj et al., 2012, Cropano et al., 2017). Another
mechanism might be that TCF7L2 regulates insulin synthesis and pro-
cessing in β cells, as suggested by the expression proﬁles of human pan-
creatic islets cells (Zhou et al., 2014). In human homozygotes for the
TCF7L2 rs7903146 T allele, pancreatic islet size is increased, β cell vol-
ume is relatively small, and glucose-stimulated insulin secretion
in vitro is reduced (Le Bacquer et al., 2012). These human data suggest
a combination of morphological and functional β cell differences
based on the T allele. Silencing of TCF7L2 in rodent islets or clonal β
cell lines also results in reduced glucose-stimulated insulin secretion,
reduced preproinsulin gene expression, reduced incretin-stimulated in-
sulin secretion, and defective exocytosis of the insulin containing gran-
ules (da Silva Xavier et al., 2009). Clearly, a number of different
mechanisms related to regulating insulin synthesis and processing in
beta cells underlie this type of genetically induced β cell dysfunction.
Numerous studies demonstrated a link between the TCF7L2
rs7903146 T allele and insulin secretion, but it is unknown if altered
de novo insulin synthesis contributes to this relationship in vivo and,
consequently, if insulin synthesis is a target for preventive strategies
for type 2 diabetes.
We recently developed a novel method that enables to follow real-
time insulin synthesis in vivo during an Oral Glucose Tolerance Test
(OGTT); with stable isotope 13C leucine used as a tracer and insulin
co-secretory product C-peptide as its target peptide for enrichmentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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insulin (Jainandunsing et al., 2016a). Here, we applied this technique
in family analyses to determine whether individuals with type 2 diabe-
tes have defective insulin synthesis, and usedMendelian randomization
with TCF7L2 rs7903146 to determine if variation of in vivo insulin syn-
thesis is causally related to type 2 diabetes.
2. Materials and Methods
2.1. Subjects
We recruited families with a high risk of type 2 diabetes by system-
atic family screening at the outpatient clinic of the Erasmus University
Medical Center as described previously (Jainandunsing et al., 2015).
Out of 83 patients with type 2 diabetes we identiﬁed 60 high-risk fam-
ilies of whom 19 Caucasian and 27 South Asian families decided to par-
ticipate in the present study. Taking patients with type 2 diabetes
attending our clinic as index cases, we recruited their ﬁrst-degree rela-
tives, taking two generations into account. Both parents of the South
Asian probands and relatives were of South Asian origin with their
roots in Surinam, and Caucasian probands and relatives were born in
the Netherlands with both parents of Caucasian Dutch origin. All indi-
viduals with type 2 diabetes were only treated with metformin and re-
ceived dietary advice. Based on the frequency of the genetic variant
rs7903146 (CT/TT), alpha 0.05, power 80%, and 1:2 ratio of affected
(type 2 diabetes) to unaffected (non-type 2 diabetes), we found that
32 individuals with type 2 diabetes and 64 without type 2 diabetes
were required for allelic test of association (Purcell et al., 2003).Weper-
formed our novel insulin synthesis test in 100 of these ﬁrst-degree rel-
atives: 48 (M18 F30) Caucasians and 52 (M26F26) South Asians. For
the OGTT, individuals were divided in subgroups with normal glucose
tolerance (NGT), impaired fasting glucose/impaired glucose tolerance
(IFG/IGT), or type 2 diabetes, based on World Health Organization
criteria. Written informed consent for the study was obtained from all
participants prior to inclusion in the study. The study protocol was ap-
proved by the Erasmus University Medical Center Medical Ethics Re-
view Board. All procedures followed were in accordance with the
ethical standards of the responsible committee on human experimenta-
tion (institutional and national) and with the Helsinki Declaration of
1975, as revised in 2008.
2.2. Anthropomorphic Data
To determine body mass index (BMI), body height and weight were
measured to the nearest 0·1 cm and 0.1 kg. Waist circumference was
measured in cm halfway between the lowest rib and the iliac crest;
the maximum circumference of the hips was measured in cm in the
standing position; and from these measurements, the waist-to-hip
(W/H) ratio was calculated.
2.3. 13C Leucine Bolus as Add-on to OGTT
We performed our protocol, immunoassay and enrichment mea-
surements as described previously and evaluated extensively
(Jainandunsing et al., 2016a). In summary: 75 g of glucosewas dissolved
in 200mLH2O and administered orally after a ten-hour overnight fast. A
bolus dose of 1 g of 13C leucinewas dissolved in 150mLH2O and admin-
istered orally 45 min (−45 min) prior to this oral glucose load. Venous
blood samples were drawn before the oral intake of the 13C leucine so-
lution (−60 min) and thereafter (−15 min) and at several time points
until 210 min after the glucose load. Urine voids were collected in the
fasting state (before oral 13C leucine solution intake) and during OGTT
(total urine collected in period after 13C leucine solution intake until
210 min after the glucose load). In these two collections, urine C-
peptide concentrations were measured, which reﬂects endogenous C-
peptide secretion (Jainandunsing et al., 2016b). The reasons for usingurine voids for our enrichmentmeasurements have been published pre-
viously (Jainandunsing et al., 2016a). For all subjects, we performed en-
richment analyses of urinary C-peptide in triplicate from the start of
solid phase extraction (SPE), which is the ﬁrst step for puriﬁcation of
C-peptide from urine. On top of basal enrichment of urinary C-
peptide, an increase in enrichment during OGTT represents de novo syn-
thesized insulin.
Details regarding the enrichmentmeasurements are mentioned in a
technical addendum elsewhere (Jainandunsing et al., 2016a). In sum-
mary: All chemicals were of analytical grade and all solvents of chro-
matographic grade and were purchased from VWR International
(West Chester, Pennsylvania, USA). Buffers and solutionswere prepared
with deionized water (Milli-Q grade). OASIS HLB cartridge columns for
SPE were purchased fromWaters (Milford, MA). The human C-peptide
mouse antibodies were purchased from HyTest Ltd (Turku, Finland).
Cyanogen-bromide-activated Sepharose 4B required for immunoafﬁni-
ty chromatography (IAC) was purchased from GE Healthcare (Diegem,
Belgium). 13C leucine (99% purity) was purchased from Cambridge Iso-
tope Laboratories. SPE followed by IAC was used for puriﬁcation of
100 pmol of absolute C-peptide from urine. Subsequently, 13C enrich-
ment in puriﬁed C-peptide was determined by gas chromatography–
mass spectrometry (GC–MS) by measuring the fragments 302 and 303
of naturally occurring and 13C-labeled leucine. GC–MS analyses of puri-
ﬁed C-peptide from all urine samples were performed with DSQ II Mass
Spectrometer Detector (Thermo Electron Corporation) and GC column
BPX5 column 25 m, I.D. 0·22 mm, ﬁlm 0·25 μm (SGE Analytical Sci-
ence). The intra and inter-variability coefﬁcient of variability of C-
peptide enrichment measurements were 1.11% and 2.34%, respectively.
2.4. Calculation of OGTT Indices and Estimated Glomerular Filtration Rate
(eGFR)
The Oral minimal model (OMM) was used to describe the plasma
glucose, insulin and C-peptide concentrations after oral glucose stimu-
lus (Breda et al., 2001).We used the C-peptideminimalmodel to assess
the following parameters for beta- cell function: the static responsivity
of β cells due to glucose potentiation,Φstatic (10−9min−1); the dynamic
responsivity of β cells due to glucose potentiation,Φdynamic (10−9); and
the total responsivity of β cells due to glucose potentiation, Φoral
(10−9min−1).We used the glucoseminimalmodel to assess the insulin
sensitivity index, SI (10−5 dL kg−1 min−1 per pM). Parameters from
bothmodelsweremultipliedwith each other to calculate the respective
disposition indices (DI): DIstatic, DIdynamic and DIoral. OMM parameters
were estimated using SAAM II software (Barrett et al., 1998). eGFR
was estimated with the modiﬁcation of diet in renal disease formula
(Levey et al., 1999).
2.5. Calculations for C-Peptide Enrichment Parameters
Enrichment parameters were expressed as tracer/tracee ratio (t/T)
derived from the levels of puriﬁed C-peptide detected in urine at base-
line and those in urine collected during the 13C leucine OGTT. The frac-
tional synthesis rate (FSR) of de novo C-peptide synthesis during OGTT
was expressed as a percentage (%/hr) and calculated using the following
formula: FSR (%/h) = (Ecollected − Ebasal)/A × 60 min × 100%, where
Ecollected is the enrichment of leucine in puriﬁed C-peptide from urine
collected during the total duration of the 13C leucine OGTT; Ebasal is the
natural enrichment in baseline urine; and area (A) is the area under
the curve in the enrichment of α-ketoisocaproic acid from 90 min to
210 min during OGTT, and used as substitute for enrichment of precur-
sor pool, which was calculated as described previously (Jainandunsing
et al., 2016a). The factor 100 is used to convert FSR into % per hour. In
cases (n = 47) where enrichment data for C-peptide from baseline
urine were missing due to low C-peptide concentrations, we used a t/
T ratio of 0.273, as this value reﬂects the natural enrichment which
was virtually universal for all individuals in our subgroups and
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cine. Total insulin synthesis during our 210 min OGTT mentioned in
Figs. 1 and 2was calculated as FSR× 2 h (period of de novo synthesis be-
tween 90 and 120 min, as mentioned previously (Jainandunsing et al.,
2016a)).
2.6. Blood Sampling for DNA Isolation and Gene Analysis of TCF7L2
rs7903146
Genomic DNA was isolated from venous whole blood sampled in
ethylenediamine tetraacetic acid tubes using a QiAamp DNA Blood
Mini Kit (QIAGEN GmbH, Hilden, Germany). Synthetic oligonucleotide
primers were used for PCR to amplify a fragment of the TCF7L2 gene
(forward primer GCCGTCAGATGGTAATGCAGAT, reverse primer CCAA
GCTTCTGAGTCACACAGGCC). Sequence analysis of the PCR product
was performed on a 310 Genetic Analyzer (ABI Prism), programmedFig. 1. a–c: Glucose, insulin and C-peptide curves during Oral Glucose Tolerance Test (OGTT) a
(c) C-peptide (below) curves during 210 min OGTT of individuals with normal glucose tolera
thin line) and type 2 diabetes (circle, thick line), respectively (mean ± SEM). Their correspon
22.1% and 27.0% (non-type 2 diabetes subgroups versus type 2 diabetes subgroup; P = .03,
synthesis rate (FSR, %/h) during Oral Glucose Tolerance Test (OGTT) with OGTT parameters. (
60min (r =−0.243, P = .015; above) and (e) between C-peptide in urine during 210 min O
tolerance (triangle), impaired fasting glucose/impaired glucose tolerance (square) or type 2 difor POP-6 polymer, 1 mL syringe, with a 47 cm, 50 i.d. capillary. The re-
trieved sequence products were used for TCF7L2 rs7903146 genotyping.
2.7. Statistical Analyses
All numerical datawere expressed asmean±SEM. Comparisons be-
tween two given subgroups were performed with an unpaired t-test.
Differences were considered statistically signiﬁcant if the P-value was
b.05. For differences between proportions, a Chi-squared test was
used; differences were considered signiﬁcant if the P-value was b.05.
Pearson's correlations were used to assess the associations between
FSR and OGTT parameters. Statistical tests were conducted using SPSS
version 20.0 for Windows (SPSS Inc., Chicago, IL, USA). Multiple regres-
sion analyses to explain variance of insulin synthesis with given inde-
pendent variables were performed using the SOLAR software package,
which takes into account family matrices (Almasy and Blangero,ccording to glucose tolerance state. (a) Plasma glucose (above), (b) insulin (middle) and
nce (triangle, dashed line), impaired fasting glucose/impaired glucose tolerance (square,
ding total insulin synthesis measurements made during OGTT are approximately 21.6%,
according to Student's unpaired t test), respectively. d–e: Correlation plot of fractional
d) Pearson's correlations between FSR and plasma C-peptide area under curve (AUC) t0-
GTT (r =−0.39, P b .001; below), respectively among individuals with normal glucose
abetes (circle).
Fig. 2. a–c: Glucose, insulin and insulin/glucose ratio curves during Oral Glucose Tolerance Test (OGTT) in type 2 diabetes subgroup according to RS7903146 genotype (f) Plasma glucose
(above), (g) insulin (middle) and (h) insulin/glucose ratio (below) curves during 210min OGTT of individuals with type 2 diabetes with either TCF7L2 RS7903146 CCwild-type genotype
(dashed line, open triangles) or CT/TT carriership (continuous line, closed triangles), respectively(mean ± SEM). Their corresponding total insulin synthesis measurements during OGTT
are approximately 20.8% versus 29.9%, respectively; P= 041, according to Student's unpaired t test.
Table 1
General characteristics of families at high risk of type 2 diabetes.
NGT IFG/IGT T2D P-value⁎
n 47 22 31
rs7903146: CC/CT/TT 29/10/8 9/10/3 10/20/1 .004†
Sex (male/female) 17/30 11/11 16/15 .330†
Age (years) 40 ± 2 44 ± 2 56 ± 2 b.001
BMI (kg/m2) 27·1 ±
0·6
29·3 ±
1·4
29·4 ±
0·8
.148
W/H ratio 0·86 ±
0·01
0·92 ±
0·2
0·94 ±
0·01
.002
SI (10−5 dL kg−1 min−1 per pM) 23 ± 3 11 ± 2 6 ± 1 b.001
DIdynamic (10−14 dL kg−1 min−1
per pM)
6263 ±
1034
2174 ±
576
545 ± 140 b.001
DIstatic (10−14 dL kg−1 min−2 per
pM)
496 ± 109 131 ± 29 47 ± 9 .005
DIoral (10−14 dL kg−1 min−2 per
pM)
569 ± 122 152 ± 33 51 ± 10 .004
FSR (%/h) 10·8 ±
0·7
11·1 ±
0·9
13·5 ±
1·3
.030
Subjects are grouped according to normal glucose tolerance (NGT), impaired fasting glu-
cose/impaired glucose tolerance (IFG/IGT) and type 2 diabetes (T2D), with numerical
data presented as mean ± SEM. BMI is body mass index; W/H ratio is waist-to-hip
ratio; SI is insulin sensitivity index derived from oral minimal model (OMM); DIdynamic,
DIstatic and DIoral are OMM-derived β cell disposition indices as described in the material
and methods section; FSR is fractional synthesis rate.
⁎ P b .05 Student's unpaired t-test of T2D versus non-T2D (NGT and IFG/IGT subgroups
combined) unless otherwise stated.
† P b .05 Chi-squared test among given subgroups.
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were considered signiﬁcant if the P-value was b.05. The datasets gener-
ated and analyzed during the current study are available from the corre-
sponding author on reasonable request.
3. Results
3.1. Insulin Synthesis Across the Stages of Glucose Tolerance
Prior to our main analysis, which is the investigation of the relation-
ship between TCF7L2 rs7903146 and insulin synthesis, we ﬁrst explored
how this novel β cell phenotype behaved across the different stages of
glucose tolerance. Based on the results of the OGTT, we obtained three
subgroups; NGT (n = 47), IFG/IG (n = 22) and non-insulin-treated
type 2 diabetes (n=31). The clinical andbiochemical features of the co-
horts are described in Table 1. Individuals with type 2 diabetes
underwent the samemodiﬁedOGTTprocedure as the non-type 2 diabe-
tes group, as they were not known with renal disease, and as, in com-
parison to the non-type 2 diabetes group, there was no difference in
eGFR (100 ± 4 versus 103 ± 3 mL/min/1.73 m2, respectively, P= .48)
and urine volume during OGTT (443 ± 60 versus 461 ± 36mL, respec-
tively, P= .79), and as there was no difference in metabolization rate of
our tracer 13C leucine between both groups (Supplemental Fig. 1). Also,
during our C-peptide puriﬁcation work-up, no additional background
contamination was observed in urine obtained from individuals with
type 2 diabetes based on the ratio between amino acids not present in
C-peptide versus amino acids that are present in C-peptide, as described
previously (Jainandunsing et al., 2016a). This implies that possible pro-
tein loss in urine among individuals with type 2 diabetes did not inter-
fere with our enrichment measurements. Our individuals with type 2
diabetes had an average disease duration of 9.8 ± 1.5 year, and they
had a higher age (P b .001) andW/H ratio (P= .002) relative to individ-
uals from the non-type 2 diabetes subgroup (NGT and IFG/IGT
combined).
In addition, we also assessed indices for insulin sensitivity and β cell
function based on the OMM, and for insulin synthesis. We found thatpatients in the type 2 diabetes subgroup had a lower SI (P b .001) and
lower β cell DI parameters (P b .001 for DIdynamic; P= .005 for DIstatic;
and P= .004 for DIoral) when compared with the non-type 2 diabetes
subgroup. The type 2 diabetes subgroup had a higher FSR (P = .030)
when compared with the non-type 2 diabetes subgroup (Table 1). For
all subgroups, OGTT plasma glucose, insulin, C-peptide curves and con-
tribution of their respective total insulin synthesis during OGTT are pro-
vided (Fig. 1a–c), aswell as correlation plots between FSR and plasma C-
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e; (r=−0.243, P= .015 and r=−0.39, P b .001, respectively).
3.2. Relationship Between T Allele of TCF7L2 rs7903146 and Insulin
Synthesis
The proportion of individuals with TCF7L2 rs7903146 CT and TT ge-
notypes increased with increasing glucose intolerance (P = .004,
Table 1). Ordinal regression analysis revealed a signiﬁcant association
between the TCF7L2 rs7903146 genotypes (CC, CT or TT) and the three
WHO OGTT categories (B = 1.06, P= .009). As we found a signiﬁcant
interaction of WHO OGTT subgroup with CC, CT or TT carriership on
the variance of FSR (βinteraction = 0.11, P = .002), we performed addi-
tional subgroup analyses to compare the effect of the presence of the
T allele on OMM indices and FSR (Table 2). In both non-type 2 diabetes
and type 2 diabetes subgroups, therewas a trend for the T-allele carriers
to have a lower SI and lower DIdynamic (P= .043 within non-type 2 dia-
betes subgroup and P=0·047within type 2 diabetes subgroup), DIstatic
andDIoral (P=0·029within type 2 diabetes subgroup)when compared
with wild-type individuals. In the type 2 diabetes subgroup, FSRwas in-
creased in the T-allele carriers compared with wild-type (P = .041).
Fig. 2a–c illustrates glucose, insulin and insulin/glucose ratio curves
with contribution of their respective total insulin synthesis during
OGTT for type 2 diabetes individuals with wild-type and T-allele
carriership. Between these groups, therewas nodifference in their aver-
age disease duration (wild-type group 9.6 ± 3.0 versus T-allele
carriership group 9.9 ± 1.8 years, P= .93) which could explain the dif-
ference in insulin synthesis.
For further in-depth analysis of the effects of the T allele on insulin
synthesis within our familymatrices, we performedmultiple regression
analyses in the non-type 2 diabetes subgroup and type 2 diabetes sub-
group. Next to ethnicity, gender, and age (and in the non-type 2 diabe-
tes subgroup also WHO OGTT category), these analyses also included
testing for a possible inﬂuence of obesity (expressed by W/H ratio), in-
sulin resistance (expressed as SI), and/or loss of ﬁrst-phase insulin re-
lease (expressed as DIdynamic), and we found opposing effects
(Table 3). In the non-type 2 diabetes subgroup, the TCF7L2 rs7903146
variant was associated with reduced insulin synthesis (β=−1.986, P
= .002), whereas in the type 2 diabetes subgroup, the TCF7L2
rs7903146 variant was associated with increased insulin synthesis (β
= 29.893, P = .01). While in our multiple regression models W/H
ratio, SI, and DIdynamic did not contribute to FSR, ethnicity did contribute
to FSR in the non-type 2 diabetes subgroup analyses. Therefore, in our
ﬁnal analysis, we also analyzed FSR in the South Asiannon-type 2 diabe-
tes and the Caucasian non-type 2 diabetes subgroups (Supplemental
Fig. 2). In the South Asian non-type 2 diabetes subgroup, the T-allele
carriers had a lower FSR than that of wild-type individuals (P= .018),Table 2
Differences between transcription factor 7-like 2 CC wild-type genotype and CT/TT carriers in
Non-T2D
TCF7L2 rs7903146 CC
n 38
NGT/(IFG/IGT) 29/9
Sex (male/female) 16/22
Age (years) 42 ± 2
BMI (kg/m2) 27·9 ± 0·9
W/H ratio 0·86 ± 0·01
SI (10−5 dL kg−1 min−1 per pM) 23 ± 3
DIdynamic (10−14 dL kg−1 min−1 per pM) 6343 ± 1175
DIstatic (10−14 dL kg−1 min−2 per pM) 462 ± 128
DIoral (10−14 dL kg−1 min−2 per pM) 537 ± 144
FSR (%/h) 11·6 ± 0·8
Non-type 2 diabetes (non-T2D) and T2D subgroups were compared, with numerical data prese
dividuals with impaired fasting glucose/impaired glucose tolerance; BMI is body mass index;
index; DIdynamic, DIstatic and DIoral are OMM derived-disposition indices for β cell function as de
⁎ P b .05 Student's unpaired t-test based on CC wild-type genotype versus CT/TT carriers in ewhile nodifferenceswere foundwithin theCaucasiannon-type 2 diabe-
tes subgroup.
4. Discussion
The results of this study show that individuals with type 2 diabetes
have defective insulin synthesis, and that this has a genetic background.
We found that the TCF7L2 rs7903146 T allele has a gene-dose effect on
insulin synthesis and on glucose tolerance status. Compared to individ-
ualswithout type 2 diabetes thosewith type 2 diabetes had higher insu-
lin synthesis and lower OMM β cell indices during OGTT, and this
increased synthesis was more prominent in individuals carrying a T
allele.
These ﬁndings are based on a stable isotope based method that al-
lows us to assess a previously undetectable parameter – newly synthe-
sized insulin. The results suggest that individuals with type 2 diabetes,
whose response to the OGTT is characterized by a reduction in both
ﬁrst-phase andoverall insulin release, dependmore on insulin synthesis
during the second phase of insulin release. Although other factors like
glucotoxicitymight lead toβ cell dysfunction in type 2 diabetes through
reduced insulin gene expression (Poitout and Robertson, 2008,
Ottosson-Laakso et al., 2017), our data demonstrate that among our in-
dividuals with type 2 diabetes there is actually a shift from readily avail-
able insulin towards increased de novo insulin synthesis. There is
increasing data about heterogeneity of β cells (Avrahami et al., 2017)
and a gradual shift towards expression of speciﬁc β cell subpopulations
that might contribute to the pathogenesis of type 2 diabetes. Out of four
subtypes of human β cell populations one subtypewith speciﬁc cell sur-
face markers was related with increased impairment of glucose-
stimulated insulin secretion in type 2 diabetes (Dorrell et al., 2016). In
mouse and human pancreas, the pattern of expression of agingmarkers
in β cells suggests that β cell heterogeneity is based on the life cycle
stage of β cells, and an increase of agingmarkers inβ cells was observed
during artiﬁcial insulin resistance (Aguayo-Mazzucato et al., 2017).
These studies support the concept ofβ cell stress and apoptosis. Another
mechanism forβ cell deﬁciency in type 2 diabetes is beta cell dedifferen-
tiation. In several animal models it has been demonstrated that hyper-
glycemic conditions can alter the differentiation status of β cells
(Talchai et al., 2012, Wang et al., 2014, Brereton et al., 2014, Szabat
et al., 2016) with loss of β cell characteristic traits and/or conversion
to other endocrine cells. The amount of dedifferentiated β cells was
found to be more prominent in pancreatic islets of humans with type
2 diabetes compared with controls (Cinti et al., 2016). Further research
is required whether a preferential secretion of de novo insulin synthesis
in our individuals with type 2 diabetes is to some degree a marker for β
cell heterogeneity under OGTT conditions in vivo. However, it is tempt-
ing to speculate that among individuals with type 2 diabetes, whooral glucose tolerance test response.
T2D
CT/TT CC CT/TT
31 10 21
18/13
12/19 7/3 9/12
40 ± 2 55 ± 3 56 ± 2
27·6 ± 0·9 30·9 ± 0·9 28·7 ± 1·0
0·90 ± 0·02⁎ 0·96 ± 0·03 0·93 ± 0·02
15 ± 3 9 ± 2 5 ± 1
3262 ± 811⁎ 1106 ± 357 278 ± 70⁎
278 ± 69 73 ± 16 34 ± 11
313 ± 75 83 ± 19 36 ± 11⁎
10·0 ± 0·6 10·4 ± 1·2 14·9 ± 1·7⁎
nted as mean ± SEM. NGT are individuals with normal glucose tolerance; IFG/IGT are in-
W/H ratio is waist-to-hip ratio; SI is oral minimal model (OMM) based insulin sensitivity
scribed in the main text; FSR is fractional synthesis rate of insulin synthesis.
ach subgroup.
Table 3
Multiple regression analyses on family matrices according to non-type 2 diabetes (non-T2D) and T2D subgroups.
Non-T2D T2D
β 95% CI P-value β 95% CI P-value
TCF7L2 rs7903146 −1·986 [−3·229;-0·743] .002 29.893 [52.768;7.018] .010
Ethnicity −2·431 [−4·024;-0·838] .003 10.083 [−8.913;29.079] .298
Gender 1·325 [−0·500; 3·150] .155 −5.415 [−22.502;11.672] .535
Age 0·136 [0·065;0·207] b.001 0.686 [−0.208;1.580] .132
W/H ratio −0·04 [−0·124;0·044] .352 0.00212 [−0.076;0.081] .958
SI 0·059 [−0·037;0·155] .229 0.233 [3.336;−2.870] .883
DIdynamic 0·0004 [−0·003;0·003] .790 −0.034 [−0.085;0.017] .191
OGTT category −0·02 [−0·044;0·004] .096 – – –
R2 48·5% 52.2%
Model trait: fractional synthesis rate (FSR) during 210min oral glucose tolerance test (OGTT). Covariates: rs7903146 (CC or CT/TT), ethnicity, gender, age, waist/hip (W/H) ratio, oral min-
imal model (OMM) based insulin sensitivity index (SI) and OMM-based disposition index DIdynamic. In themodel for the non-T2D subgroup, we also includedWHOOGTT category as co-
variate. Bold values indicate P-values that reached b.05 signiﬁcance.
300 S. Jainandunsing et al. / EBioMedicine 30 (2018) 295–302already have reduced β cell mass secondary to apoptosis and/or dedif-
ferentiation, the in vivo higher demand for insulin synthesis might fur-
ther contribute to β cell heterogeneity, exhaustion and eventually
apoptosis, and consequently also be one of the underlying causes of
loss of β cell mass. In addition and accompanying increased insulin syn-
thesis, an increased release of insulin-co-release products like islet am-
yloid polypeptide, which has cytotoxic effects on β cells (Westermark
et al., 2011), as well as ATP, which might increase islet inﬂammation
through activation of islet macrophages (Weitz et al., 2018), could con-
tribute to enhanced β cell deterioration. Our methodology is less suited
for studies of insulin-treated type 2 diabetes, therefore our group of in-
dividuals with type 2 diabetes may have been in a relatively homoge-
neous early stage of the disease. Future prospective studies focused on
how insulin synthesis is linked to the duration of the disease are re-
quired for additional insights in pathogenesis and progression of type
2 diabetes.
The ﬁndings among individuals with type 2 diabetes were even
more pronounced in T-allele carriers. This increase in insulin synthesis
in T-allele carriers who have non-insulin-treated type 2 diabetes
might be explained by other factors that studies associated with
TCF7L2 SNPs; these include reduced early phase insulin secretion
(Loos et al., 2007, Alibegovic et al., 2010), reduced exocytosis (da Silva
Xavier et al., 2009), impaired proinsulin-to-insulin conversion (Loos
et al., 2007, Kirchhoff et al., 2008, Stolerman et al., 2009), and decreased
β cell mass (Le Bacquer et al., 2012). One may even argue that, because
the TCF7L2 rs7903146 variant is associated with type 2 diabetes, all
other factors associated with type 2 diabetes will also be associated
with the TCF7L2 variant. However, although TCF7L2 rs7903146 indeed
has a consistent and relatively strong association with type 2 diabetes,
it explains only a negligible fraction of the heritability of type 2 diabetes.
One could also comment that defective insulin synthesis is not a cause of
type 2 diabetes, but that it is rather just a secondary factor associated
with the disease. However, we observed a more intricate relationship
based on a signiﬁcant genetic interaction that conﬁrms the effect of
the TCF7L2 rs7903146 variant on insulin synthesis within type 2 diabe-
tes. Also, in our multiple regression model, ﬁrst-phase insulin release
did not contribute to FSR. Nevertheless, TCF7L2 is known to inﬂuence
the expression of multiple genes in different pathways (Zhou et al.,
2014, Mitchell et al., 2015) and our ﬁndings do not rule out this
pleiotropy.
Our ﬁnding that South Asian TCF7L2 T-allele carriers without type 2
diabetes had lower insulin synthesis than their wild-type counterparts
was not unexpected. An inability to increase insulin secretion to com-
pensate for insulin resistance has been previously demonstrated
among healthy T-allele risk carriers in whom insulin resistance was ar-
tiﬁcially induced (Alibegovic et al., 2010). Also, in a recently published
multi-ethnic cohort study comprising of obese adolescents, the TCF7L2
rs7903146 was related to impaired β cell function and led to an in-
creased risk of progression from prediabetes to type 2 diabetes(Cropano et al., 2017). As insulin resistance is a key characteristic of
our South Asian population, this might explain the differences between
T-allele risk carriers and wild-type that were apparent in South Asians
without type 2 diabetes, while such differences were not seen in Cauca-
sians without type 2 diabetes. This reduction in insulin synthesis might
contribute to their risk of type 2 diabetes. Strikingly, the average age of
onset of type 2 diabetes was 12 years earlier in our South Asian popula-
tion than in the Caucasians. This does tie in with the fact that the prev-
alence of type 2 diabetes is known to be nearly ﬁvefold higher among
South Asians than among indigenous Dutch (Bindraban et al., 2008,
Chandie Shaw et al., 2006). Previously, we have reported homogenous
insulin-resistant conditions in South Asian families regardless of their
glucose tolerance (Jainandunsing et al., 2015), and their insulin resis-
tancemight also augment the harmful effects of β cell-related gene var-
iants other than those of TCF7L2. However, the increase in insulin
synthesis that we observed in individuals with type 2 diabetes during
the OGTT in this study indicates an opposite effect under hyperglycemic
conditions, underlining the likelihood that glucose levels also inﬂuence
the TCF7L2 variant effect. This previously unrecognized interactionwar-
rants future research into the inﬂuence of a glucose stimulus on multi-
functional aspects of β cell pathways, as we cannot exclude the
possibility that for other genotypes the β cell phenotype will also de-
pend on whether or not the person has type 2 diabetes. Future studies
with individuals with type 2 diabetes versus controls with artiﬁcially in-
creased glucose levels are required to provide more insights in this
interaction.
In terms of technical problems, a relatively large number of subjects
had very low basal C-peptide concentrations in combination with rela-
tively low basal volumes of urine and consequently we were unable to
harvest enough amounts of absolute C-peptide for enrichment mea-
surements. Although subjects were asked to empty their bladders at
baseline, they might have already emptied their bladders at home
prior to the start of the OGTT. Despite these technical problems, basal
urine C-peptide enrichment measurements provided stable values for
all subgroupswith a small variance and correspondswith the calculated
theoretical natural isotope ratio in leucine. Although we had expected
difﬁculties with the urinary C-peptide enrichment measurements for
individuals with type 2 diabetes due to protein contamination, such
problems did not arise, probably because these patients had no history
of diabetic nephropathy and they were not (yet) taking insulin. Our C-
peptide antibodies used for the IAC procedure for C-peptide puriﬁcation
have cross-reactivity with insulin precursor proinsulin. However, the
excretion of proinsulin in urine is negligible compared to C-peptide,
with daily urinary excretion of 0.05% versus 5–10% of pancreatic secre-
tion, respectively (Constan et al., 1975). Subsequently, during the pro-
cess towards actual enrichment measurements of urinary C-peptide,
we did not ﬁnd evidence that proinsulin or other insulin precursors
played a signiﬁcant role in affecting these measurements. These and
other technical issues have been described previously (Jainandunsing
301S. Jainandunsing et al. / EBioMedicine 30 (2018) 295–302et al., 2016a). Interestingly, because of the cross-reactivity trait of the
antibodies used, future research focused on a similar puriﬁcation meth-
odology in plasma could provide us with in-depth real-time analyses of
rs7903146 effects on proinsulin processing.
This is the ﬁrst time that stable isotope-based tracer technique has
been used to measure insulin synthesis and secretion in individuals
with glucose intolerance, and the ﬁrst time such an approach has been
applied to analyze the pathogenesis of type 2 diabetes. Our test was
able to ﬁnd differences between individuals with andwithout type 2 di-
abetes as well as between TCF7L2 T-allele carriers and C-allele homozy-
gotes. Based on our enrichment data, late phase hyperinsulinemia
observed in early stages of type 2 diabetes not only reﬂects a decrease
of insulin sensitivity and insulin clearance (Kim et al., 2017), but also
points at abnormal β cell function with a change in dynamics of insulin
secretion in the context of a programmed increase of insulin synthesis.
Moreover, this alteredβ cell functionwith increased insulin synthesis it-
self might be a signiﬁcant contributor for sustaining insulin resistance
(Templeman et al., 2017). In particular, it might partially explain why
lifestyle intervention in individuals with type 2 diabetes for the over-
whelming majority does not lead to partial or complete remission of
their disease (Gregg et al., 2012). Future research focused on further as-
sessment of the pathophysiology of this increased insulin synthesis
state may provide opportunities for further development of speciﬁc
therapies to decrease the demand for insulin synthesis.
In conclusion, using a novel stable isotope-based technique to follow
de novo insulin synthesis in vivo, we have found that the TCF7L2
rs7903146 gene variant provides a link between type 2 diabetes and
variations in the levels of newly synthesized insulin. Our ﬁndings sug-
gest that the glucose-sensitive TCF7L2 pathway is a potential target for
interventions that prevent type 2 diabetes.
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